Atossa Therapeutics
ATOS
51 hedge funds and large institutions have $9.49M invested in Atossa Therapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 12 closing their positions.
601% more call options, than puts
Call options by funds: $925K | Put options by funds: $132K
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0.06% less ownership
Funds ownership: 1% → 0.94% (-0.06%)
9% less funds holding
Funds holding: 56 → 51 (-5)
40% less capital invested
Capital invested by funds: $15.8M → $9.49M (-$6.36M)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$135K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$88.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$34.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$30.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$264K |
| 2 |
D.E. Shaw & Co
New York
|
-$224K |
| 3 |
Renaissance Technologies
New York
|
-$192K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$159K |
| 5 |
Millennium Management
New York
|
-$81.3K |
ATOS Hedge Fund Activity: Q4 2022 in Review
51 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2022, worth a combined $9.49M — down 40% from $15.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATOS and 7 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $135K. The largest seller was Ergoteles, exiting entirely with an estimated $264K sold.
- 51 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2022, down from 56 in Q3 2022.
- Funds reported $9.49M of Atossa Therapeutics stock for Q4 2022, down 40% quarter-over-quarter.
- 7 funds opened new Atossa Therapeutics positions in Q4 2022 and 12 closed out, a net change of -5 holders.
- The largest Atossa Therapeutics buyer in Q4 2022 was Bank of Montreal, an estimated $135K added.
- The largest Atossa Therapeutics seller in Q4 2022 was Ergoteles, an estimated $264K sold.
Based on aggregated 13F filings for Q4 2022.